Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript
Acadia Pharmaceuticals (NASDAQ:ACAD) reported Q2 2026 total revenues of $308 million, up 17% year over year, driven by DAYBUE and NUPLAZID demand. Management raised 2026 DAYBUE sales guidance to $480 million-$510 million and updated total revenue guidance to $1.24 billion-$1.30 billion. Cash and investments were $956 million as of June 30, 2026.
How this was made
The 30-second read
Why it matters
The newest actionable information is management’s updated 2026 guidance (DAYBUE, total revenue) and the associated drivers (powder formulation volume growth, gross-to-net adjustments), plus concrete upcoming clinical and regulatory milestones.
Market read
Traders can reprice 2026 revenue expectations based on raised DAYBUE and total revenue guidance, while monitoring near-term catalysts tied to formulation adoption and upcoming clinical/regulatory readouts.
What to watch
R&D guidance reduction is attributed to a business development milestone shifting to 2027, which may defer spend and could signal timing risk for downstream development activities.
Background
The piece is a transcript-style summary of Acadia Pharmaceuticals’ Q2 2026 earnings call, covering commercial performance for DAYBUE and NUPLAZID and pipeline/regulatory updates.
Ticker impact
Acadia raised 2026 DAYBUE sales guidance to $480 million to $510 million and updated total 2026 revenue guidance to $1.24 billion to $1.30 billion.
Likely positive bias for near-term trading as raised guidance and higher franchise demand can support estimates and sentiment, though volatility remains around pipeline timelines.
The article provides multiple concrete, management-attributed guidance and commercial metrics (DAYBUE/NUPLAZID sales, gross-to-net, cash balance) plus specific upcoming milestones (remlifanserin Phase II top-line in Sep-Oct 2026, trofinetide Germany early Q4 2026).
Market effects
Reinforces demand and pricing dynamics for specialty CNS franchises, potentially affecting sentiment toward other rare-disease and neuropsychiatry drug developers.
Europe expansion plans (Germany early Q4 2026) may influence expectations for payer access and launch execution in EU markets.
Japan and Europe regulatory timelines (PMDA and EMA/CHMP processes) highlight cross-region execution risk for CNS pipeline programs.
Counterpoint
Raised guidance could already be partially anticipated; the market may focus on whether gross-to-net and volume trends can sustain through 2H and whether pipeline milestones slip.
Key entities
- companyAcadia Pharmaceuticals
NASDAQ-listed specialty pharma reporting Q2 2026 results and updating 2026 guidance for DAYBUE, NUPLAZID, and total revenue.
- productDAYBUE
Rett syndrome treatment whose powder formulation adoption is cited as driving higher 2026 sales guidance.
- productNUPLAZID
Alzheimer’s disease psychosis and Lewy body dementia psychosis treatment with reaffirmed 2026 sales guidance.
- pipelineremlifanserin
Lead candidate with Phase II RADIANT program enrollment completion and top-line results expected Sep-Oct 2026.
- pipelinetrofinetide
Program with planned Germany launch in early Q4 2026 and additional European market access submissions in 2026.
